Although post-therapy Ki-67 may be a better biomarker than the change in Ki-67 (in the context of predicting breast cancer recurrence) [4], other possible contributing factors are attributable to the preliminary nature of our pilot study. Here, MKI67 is linked to breast carcinoma.